Market revenue in 2023 | USD 8.2 million |
Market revenue in 2030 | USD 24.5 million |
Growth rate | 17% (CAGR from 2023 to 2030) |
Largest segment | Neurology |
Fastest growing segment | Orthopedic |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Dental, Orthopedic, Neurology |
Key market players worldwide | GlaxoSmithKline, Hewlett Packard Enterprise Co, Merck KGaA, AstraZeneca PLC, Aprecia Pharmaceuticals, Extend Biosciences, BioDuro, Affini-T Therapeutics, Osmotica Pharmaceutical, FabRx, Cycle Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to 3d printed drugs market will help companies and investors design strategic landscapes.
Neurology was the largest segment with a revenue share of 50% in 2023. Horizon Databook has segmented the Japan 3d printed drugs market based on dental, orthopedic, neurology covering the revenue growth of each sub-segment from 2018 to 2030.
The Japan 3D printed drugs market is currently witnessing growth, primarily driven by various factors shaping the country's healthcare & biotechnology landscape. A key driver for this expansion is the rapidly aging population, which has created a pressing need for innovative medical solutions.
Owing to various factors, including a declining birth rate and increased life expectancy, it is projected that by 2060, the proportion of people aged 65 & older will surge to nearly 38% of the total population. As the elderly demographic continues to expand, the demand for personalized healthcare is expected to grow.
Furthermore, Japan has a robust healthcare infrastructure and a culture of embracing innovation in the medical field, fostering a conducive environment for the adoption and advancement of 3D printed drugs. Furthermore, the Japanese government's support and initiatives to promote R&D in advanced manufacturing provide a favorable landscape for pharmaceutical companies to invest in this technology.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan 3d printed drugs market , including forecasts for subscribers. This country databook contains high-level insights into Japan 3d printed drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account